Navigation Links
Isis Reports Financial Results and Highlights for Third Quarter 2012
Date:11/6/2012

CARLSBAD, Calif., Nov. 6, 2012 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) today reported a pro forma net operating loss (NOL) of $26.0 million and $36.0 million for the three and nine months ended September 30, 2012, respectively, compared to a pro forma NOL of $20.0 million and $44.9 million for the same periods in 2011. The Company ended the third quarter of 2012 with $343.6 million in cash. 

"We have had a very successful year. With a number of exciting events on the horizon, the remainder of 2012 promises to be equally eventful. Of course, the most notable events this year are associated with KYNAMRO™. We are pleased with the positive recommendation from the FDA's advisory committee for KYNAMRO and look forward to the FDA's decision early next year. We believe KYNAMRO could have a profound impact on the lives of patients with homozygous FH, who are at extreme cardiovascular risk and are in need of new therapeutic options. We look forward to bringing this important new medicine to these patients," said B. Lynne Parshall, Chief Operating Officer and Chief Financial Officer at Isis. 

"While KYNAMRO is the most notable of our successes, we have had many achievements across our pipeline. Most recently, we have completed key steps to move two of our severe and rare disease drugs toward commercial markets. We initiated the next clinical study in patients with spinal muscular atrophy for our drug, ISIS-SMNRx, which we partnered with Biogen Idec earlier this year. This study will be a relatively short study and will position us to initiate a registration-directed Phase 2/3 study next year. In addition, we and GSK amended the development plan for ISIS-TTRRx to employ a more efficient route to the market. We plan to initiate the Phase 2/3 study evaluating ISIS-TTRRx'/>"/>

SOURCE Isis Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine technology :

1. MEI Pharma Reports New Data Showing High Response Rates in Clinical Trial of Pracinostat and Azacitidine in Myelodysplastic Syndrome
2. CVS Caremark Reports Third Quarter Results
3. Lexicon Pharmaceuticals Reports on Clinical Program Status and 2012 Third Quarter Results
4. Cytos Biotechnology Ltd Reports Third Quarter 2012 Financial Results, Recent Development and Outlook
5. Covance Reports Third Quarter Pro Forma Net Revenue Of $542 Million, Pro Forma EPS Of $0.72 And Adjusted Net Orders Of $701 Million
6. Depomed Reports Third Quarter Financial Results
7. Cambrex Reports Third Quarter 2012 Financial Results
8. Cadence Pharmaceuticals Reports Third Quarter 2012 Financial Results
9. Express Scripts Reports Third Quarter Results
10. ADVENTRX Reports Third Quarter 2012 Financial Results
11. Endo Reports Third Quarter Financial Results And Updates 2012 Financial Guidance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... China separating membrane market has witnessed robust development ... years, albeit as a later starter. In 2012, the size ... approximated RMB12 billion, with the proportion worldwide soaring to 16.3%. ... membrane market will continue its growth rate by around 20% ... will jump to roughly RMB25 billion. An integrated ...
(Date:12/17/2014)... , Dec. 17, 2014  Northstar Global Business ... Trust Company (DTC) has made their final decision ... on the Company,s stock effective December 15, 2014, ... stock for depository and book entry transfer services. All ... is now once again fully "DTC Eligible", and ...
(Date:12/17/2014)...  IGI Laboratories, Inc. (NYSE MKT: IG; "IGI" or ... of $125 million aggregate principal amount of 3.75% Convertible ... offered and sold only to qualified institutional buyers pursuant ... as amended (the "Securities Act"). The Notes ... year, payable semiannually in arrears on June 15 and ...
Breaking Medicine Technology:Separation Membranes Market (Company, Country & Application) Research Reports for Global and Chinese Regions 2Separation Membranes Market (Company, Country & Application) Research Reports for Global and Chinese Regions 3Northstar announces that the DTC chill on MDIN has been officially lifted 2Northstar announces that the DTC chill on MDIN has been officially lifted 3IGI Laboratories Announces Closing of $125 Million of 3.75% Convertible Senior Notes Due 2019 2IGI Laboratories Announces Closing of $125 Million of 3.75% Convertible Senior Notes Due 2019 3IGI Laboratories Announces Closing of $125 Million of 3.75% Convertible Senior Notes Due 2019 4
... plc , (LSE: SHP, Nasdaq: SHPGY ), the ... and Drug Administration (FDA) approved the use of once-daily ... for the treatment of attention deficit hyperactivity disorder (ADHD) in ... a total treatment program. The approval is based on results ...
... YORK, Feb. 28, 2011 Keryx Biopharmaceuticals, Inc. (Nasdaq: ... the Company,s Chief Executive Officer, will be presenting at ... Conference (New York, NY)Wednesday, March 2, 201111:00am ETCowen & ... MA)Monday, March 7, 2011 4:45pm ETROTH 23rd Annual OC ...
Cached Medicine Technology:FDA Approves INTUNIV® (guanfacine) Extended-Release Tablets for Use as Adjunctive Therapy to Stimulants for the Treatment of ADHD in Children and Adolescents 2FDA Approves INTUNIV® (guanfacine) Extended-Release Tablets for Use as Adjunctive Therapy to Stimulants for the Treatment of ADHD in Children and Adolescents 3FDA Approves INTUNIV® (guanfacine) Extended-Release Tablets for Use as Adjunctive Therapy to Stimulants for the Treatment of ADHD in Children and Adolescents 4FDA Approves INTUNIV® (guanfacine) Extended-Release Tablets for Use as Adjunctive Therapy to Stimulants for the Treatment of ADHD in Children and Adolescents 5FDA Approves INTUNIV® (guanfacine) Extended-Release Tablets for Use as Adjunctive Therapy to Stimulants for the Treatment of ADHD in Children and Adolescents 6Keryx Biopharmaceuticals Announces Upcoming Corporate Presentations 2
(Date:12/21/2014)... 21, 2014 AngelWeddingDress.com’s new collection of ... a total of 1,000 new designs in this collection, ... spring 2015. , AngelWeddingDress.com promises to provide ... with wardrobe essentials while many fashion trends come and ... customer service team at AngelWeddingDress.com is ready to assist. ...
(Date:12/21/2014)... (PRWEB) December 21, 2014 Recently, one ... world, LunaDress Prom Shop has introduced its ... Christmas Sale, offering big discounts on all its prom ... off. , LunaDress insists on providing top quality dress ... and it is considered as one of the best ...
(Date:12/21/2014)... (PRWEB) December 21, 2014 Serious Buyer, ... for Vintage 1967 Jm Morrison and the Doors International Ballroom ... This would also be the only time that Morrison's ... was on Nov. 25, 1967. According to Hawley, “This ... They did play the Alexandria Roller Rink earlier that ...
(Date:12/21/2014)... 2014 SCI explores disability ... and systemic barriers for disabled athletes with Aaron ... has a condition called juvenile macular degeneration, where he ... he adapted his athletic ambitions to his vision and ... triathlon to pioneer the way for other blind and ...
(Date:12/21/2014)... (PRWEB) December 21, 2014 CannabisClassifieds.com celebrates marijuana’s ... The only one of its kind, the site has ... local marijuana for 14 years running. It uniquely combines ... to make cannabis readily available to the masses. Assuring ... grasping the golden ring of public approval. , ...
Breaking Medicine News(10 mins):Health News:2015 Spring Wedding Dresses From AngelWeddingDress Just Released 2Health News:New Prom Dresses From One Of The Best Prom Dresses Online Shops, LunaDress Prom Shop 2Health News:Disability in Sports on SCI TV with Triathlon World Champ Aaron Scheidies 2Health News:Disability in Sports on SCI TV with Triathlon World Champ Aaron Scheidies 3Health News:CannabisClassifieds.com Maintains its “Craigslist for Cannabis” Standing with Website Re-launch 2
... diet, researchers say , WEDNESDAY, July 8 (HealthDay News) -- ... common amino acids in vegetable protein seems to lower blood ... shows that a 4.72 percent higher intake of glutamic acid ... 1.5- to 3-point reduction in average systolic blood pressure (the ...
... 8 Transdel Pharmaceuticals, Inc. (OTC Bulletin Board: ... non-invasive, topically administered products, today announced they have ... pivotal Phase 3 clinical study for Ketotransdel(R), a ... acute pain. , , Based on ...
... N.Y., July 8 The Max Cure Foundation -- a ... -- announced today its first charity benefit, the first annual ... take place on Saturday, August 22, from 2:00 - 6:00 ... the East Hampton Indoor Tennis Club, 175 Daniels Hole Road, ...
... July 8 Perot Systems Corporation (NYSE: ... an agreement with the Hunan Provincial Government of the ... to provide IT consulting services for healthcare organizations and ... the Provincial Government and in alignment with the Chinese ...
... ... High Definition videoconferencing, audiovisual (AV), networked solutions and services to offer video conferencing ... global room affiliates. , ... Denver, CO and Camarillo, CA (PRWEB) July 8 -- Affinity ...
... ... popularity. These parts washers are cost effective and quick solutions for companies that need ... ... Midbrook, a Jackson, MI based manufacturer of industrial parts washing systems, medical decontamination systems, ...
Cached Medicine News:Health News:Vegetable Amino Acid Lowers Blood Pressure 2Health News:Vegetable Amino Acid Lowers Blood Pressure 3Health News:Transdel Pharmaceuticals Completes Enrollment in Phase 3 Clinical Study for Novel Topical Pain Treatment 2Health News:Transdel Pharmaceuticals Completes Enrollment in Phase 3 Clinical Study for Novel Topical Pain Treatment 3Health News:The Max Cure Foundation Announces Its First Charity Benefit: The 'Roar for a Cure' Carnival to Be Held on Saturday, August 22, 2009 2Health News:The Max Cure Foundation Announces Its First Charity Benefit: The 'Roar for a Cure' Carnival to Be Held on Saturday, August 22, 2009 3Health News:The Max Cure Foundation Announces Its First Charity Benefit: The 'Roar for a Cure' Carnival to Be Held on Saturday, August 22, 2009 4Health News:The Max Cure Foundation Announces Its First Charity Benefit: The 'Roar for a Cure' Carnival to Be Held on Saturday, August 22, 2009 5Health News:Perot Systems Selected to Implement Health Information Systems in China 2Health News:Perot Systems Selected to Implement Health Information Systems in China 3Health News:Affinity VideoNet Partners With Providea Conferencing 2Health News:Affinity VideoNet Partners With Providea Conferencing 3Health News:Refurbished and Used Industrial Parts Washers Grow in Popularity 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: